Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Buspirone
6 evidence topics · 4 sources
FDA-approved indication and duration of demonstrated efficacy
Adverse events and discontinuation in premarketing trials
Abuse and dependence potential
CANMAT guideline: second-line agent
“Buspirone was more effective than placebo and as effective as benzodiazepines in several RCTs (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limited effectiveness in clinical practice relegates buspirone to a second-line agent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: acute efficacy without relapse-prevention evidence
Cochrane review of azapirones
“Thirty six trials were included in the review, reporting on 5908 participants randomly allocated to azapirones and/or placebo, benzodiazepines, antidepressants, psychotherapy or kava kava. Azapirones, including buspirone, were superior to placebo in treating GAD. The calculated number needed to treat for azapirones using the Clinical Global Impression scale was 4.4 (95% confidence interval (CI) 2.16 to 15.4). Azapirones may be less effective than benzodiazepines and we were unable to conclude if azapirones were superior to antidepressants, kava kava or psychotherapy. Azapirones appeared to be well tolerated. Fewer participants stopped taking benzodiazepines compared to azapirones. The length of studies ranged from four to nine weeks, with one study lasting 14 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Longer term studies are needed to show that azapirones are effective in treating GAD, which is a chronic long‐term illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote